Odysight.Ai Inc. 10-Q Summary: Q2 2024
Business Context and Reporting Period
Odysight.Ai Inc. (formerly ScoutCam Inc.) is a Nevada-based company developing AI-powered video sensor platforms for Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) in aviation, transportation, energy, and medical sectors. This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $1.181 million | $1.368 million | $0.674 million | $0.977 million |
| Gross Profit | $0.514 million | $0.291 million | ($0.103 million) | ($0.350 million) |
| Operating Loss | ($2.364 million) | ($5.728 million) | ($3.119 million) | ($5.898 million) |
| Net Loss | ($2.182 million) | ($5.344 million) | ($2.876 million) | ($5.562 million) |
| Cash & Equivalents | $13.238 million (as of June 30, 2024) | |||
| Accumulated Deficit | ($39.551 million) (as of June 30, 2024) |
Liquidity & Debt: The company reported no long-term debt. Total liabilities were $5.148 million, primarily consisting of contract liabilities ($2.195 million) and operating lease liabilities ($1.123 million). Cash used in operating activities for the six months ended June 30, 2024, was $3.323 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 75% in Q2 2024 compared to Q2 2023, driven by increased unit sales and higher pricing from a Fortune 500 healthcare customer, alongside new Industry 4.0 revenue.
- Gross Margin Turnaround: The company transitioned from a gross loss in Q2 2023 to a gross profit of $0.514 million in Q2 2024. This was achieved through higher unit prices, increased volume, and reduced material costs.
- Expense Management: Sales and marketing expenses decreased 54% year-over-year in Q2 2024, largely due to the absence of one-time rebranding costs and the Paris Air Show participation incurred in 2023. Conversely, General and Administrative (G&A) expenses rose 7% due to new professional services and stock-based compensation.
- Operating Loss Reduction: The operating loss narrowed by 24% in Q2 2024 compared to the prior year period.
Outlook, Risks, and Subsequent Events
- Subsequent Financing: On July 16, 2024, the company completed a private placement raising approximately $10.3 million by issuing 2,144,583 shares at $4.80 per share.
- Liquidity Outlook: Management believes current cash resources, combined with the recent financing, will fund operations for at least the next 12 months. However, the company expects to continue incurring significant R&D and commercialization costs and will require additional funding to reach profitability.
- Risks: The company faces risks related to its start-up nature, dependence on a limited number of customers (including the key healthcare client), and the need for future capital raises which may result in dilution. There is no assurance that operations can be maintained at current levels or that capital can be raised on acceptable terms.
- Forward-Looking Statements: The filing includes standard disclaimers regarding future projections, noting that actual results may differ materially due to various uncertainties.
Key Facts for Investor Verification
- Customer Concentration: Verify the sustainability of revenue growth given the heavy reliance on a single Fortune 500 healthcare customer for a substantial portion of recent revenue.
- Cash Burn Rate: Monitor the monthly cash burn rate against the newly raised $10.3 million to confirm the 12-month runway estimate.
- Warrant Overhang: Note the existence of approximately 5.76 million outstanding warrants (from 2021 and 2023 private placements) with exercise prices ranging from $5.50 to $10.35, which could impact future dilution.
- Revenue Recognition: Review the specific terms of the healthcare contract, as revenue includes both product sales and amortized development services over a seven-year term.